2025年5月27日,中银国际作为联席全球协调人、联席账簿管理人及联席牵头经办人协助派格生物(股票代号:2565.HK)在香港联合交易所成功上市。派格生物是一家专注于以肽和小分子药物治疗慢性病的生物技术公司。上市概况派格生物此次全球发行19,283.500股H股,发行价格定于每股15.6港元,总募集金额约3亿港币。此次派格生物在香港公开发售项下,公司合共接获约5万份有效申请,认购股数约为香港...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.